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Oncogene-induced senescence (OIS) is thought to be a barrier to malignant transformation resulting from
the strong activation of oncogenes. In this issue of Cancer Cell, Damsky and colleagues suggest activation
of mTORC1 and mTORC2 is required for OIS evasion in human melanomas harboring oncogenic BRAF
mutations.Cellular senescence was described more
than five decades ago as an in vitro
permanent growth arrest in primary fibro-
blasts after long-term culture. Subse-
quent work has shown that senescence
can be induced by a wide variety of
extra- and intracellular stresses. The
molecular effectors of senescence have
been well characterized, involving the
activation of canonical tumor suppres-
sors like p53, p16Ink4a, and RB (Kuilman
et al., 2010). Perhaps one of the most
surprising findings regarding senescence
has been the discovery that the strong
activation of certain oncogenes, the
very agents of cancer, will potently
induce senescence in cells with intact
p53 and p16Ink4a-RB signaling (Serrano
et al., 1997). The discovery of this ‘‘onco-
gene-induced senescence’’ (OIS) has
troubled many cancer researchers. How
could any normal cell ever give rise to a
cancer if oncogene activation provokes
a permanent growth arrest? A variety of
explanations have been advanced in an
attempt to resolve this seeming paradox.
A few of the more popular notions have
been that OIS (or even senescence in
general) is merely an in vitro artifact,that p53 or p16Ink4a loss actually pre-
cedes strong oncogene activation in can-
cers, or that cellular senescence is in
some cases not permanent as previously
conceived.
Support for the occurrence of OIS
in vivo is probably stronger for melanoma,
a common and lethal human skin cancer,
than for any other form of human cancer.
The overexpression of common onco-
genic drivers of melanoma, e.g., mutant
Nras or Braf, potently inducesmelanocyte
OIS in vitro in a p16Ink4a- and p53-depen-
dent manner. The expression of markers
of senescence such as p16Ink4a can be
demonstrated in precursor lesions of mel-
anoma (nevi) harboring BRAF mutations,
most commonly V600E. These observa-
tions have suggested that many nevi are
would-be cancers but are successfully in-
terdicted by the senescence machinery.
The fact that the vast majority of nevi
never progress to melanoma speaks to
the robustness of OIS as a defense mech-
anism against cancer. It appears clearly
true, however, that cells in a very small
fraction of nevi evade OIS to cause the
roughly 70,000 melanoma cases per
year in the US alone.Against this background, Damsky et al.
(2015; in this issue of Cancer Cell) have
tackled theOIS problem, focusing onmel-
anoma. To do this, the authors use an
array of state-of-the-art conditional mu-
rine models to comprehensively analyze
the transitions from prearrested, to post-
arrested, to transformed melanocytes.
In accord with prior work (Dhomen et al.,
2009; Michaloglou et al., 2005), the au-
thors demonstrate that disruption of the
Cdkn2a (Ink4a/Arf) locus alone is not
sufficient to permit BrafV600E-inducedme-
lanoma, suggesting that activated Raf
signaling engages an antiproliferative res-
ponse independent of Cdkn2a signaling
(Figure 1). This observation is in accord
with prior work suggesting that activated
Ras-Raf signaling induces a compensa-
tory repression of PI3K-Akt and Raf-Mek
signaling (Courtois-Cox et al., 2006). In
the present study, however, the combi-
nation of Braf activation and Cdkn2a
loss was sufficient to prime progression
of nevi to melanoma, presumably in the
setting of additional stochastic events.
By including a GFP expressed specifically
in melanocytes in their murinemodels, the
authors were able to purify uncultured27, January 12, 2015 ª2015 Elsevier Inc. 3
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Figure 1. Bypassing of OIS in Melanocytes and Progression to Melanoma
(A) In the presence of activated BrafV600E, expression of Pten, Lkb1, and Ink4a/Arf (Cdkn2a locus) in me-
lanocytes inhibits both mTORC1 and mTORC2 signaling, impeding cell growth and proliferation, resulting
in oncogene-induced senescence.
(B) Inactivating mutations of Pten, Lkb1, and Cdkn2a in postarrested melanocytes result in elevated
mTORC1/2 signaling and enhanced proliferation, bypassing senescence, and promoting transformation
to melanoma.
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Previewsprimary melanocytes that were prear-
rested, postarrested, or transformed. Un-
biased RNA expression analysis of the
three purified populations showed that
mTOR signaling was strongly downregu-
lated in arrestedmelanocytes but upregu-
lated with progression to melanoma
(Figure 1). mTOR signaling plays a crucial
role in cell metabolism and proliferation
and carries out its functions via two multi-
protein complexes (TORC1 and TORC2).
The mTOR pathway has been an attrac-
tive cancer therapeutic target, with se-
veral inhibitors in clinical trials or recently
approved by the Food and Drug Adminis-
tration of the USA (e.g., everolimus) as
antineoplastics.
In order to explore Braf-induced senes-
cence, the authors inactivated the Lkb1
(Stk11) tumor suppressor in the presence
of activated Braf in melanocytes. LKB1,
inactivated through deletion or point mu-
tation in 5%–10% of human melanoma,
encodes a pleiotropic kinase with nu-
merous functions, including the ability to
inhibit the activity of mTORC1 (Shaw
et al., 2004). Loss of Lkb1 promoted
bypass of OIS, allowing for persistent
low levels of proliferation, but progression
to aggressive melanoma was not ob-
served. A rapid bypass of OIS with mela-
noma formation was achieved when
the authors inactivated both Lkb1 and
Cdkn2a in the context of Braf activation,
suggesting strong Raf activation engages4 Cancer Cell 27, January 12, 2015 ª2015 Elantiproliferative effects via mTOR repres-
sion and Cdkn2a activation (Figure 1B).
The authors also noted a repressive effect
of Lkb1 on melanoma metastasis, which
has been suggested to be mTOR-inde-
pendent in prior studies (Liu et al., 2012).
To further analyze the role of mTOR
signaling, the authors turned to a well-
characterized Pten;Braf melanoma mo-
del, where concomitant Pten inactivation
and Braf activation potently cooperate
to rapidly induce murine cancers. In this
system, the authors targeted specific
components of the mTORC1 or mTORC2
complex to show that activation of both
mTORC1 and Akt-mTORC2 were neces-
sary for melanoma formation. Finally, the
authors demonstrated a role for the
miRNA99/100 family in preventing pro-
gression of nevus to melanoma by inhibit-
ing an IGF1R-mTOR pathway.
These results are in accord with
ongoing deep sequencing studies, such
as The Cancer Genome Atlas, of somatic
mutations in human cancer. Such studies
have suggested essentially four types of
melanoma: BRAF mutant (50%), NRAS
mutant (30%), NF1 mutant (10%), and so
called ‘‘wild-type’’ mutant (10%). Most
mutations of PTEN and LKB1 co-occur
with BRAF mutation, suggesting that
activated Ras signaling that results from
mutations of NRAS or NF1 sufficiently
activates mTOR signaling to promote
tumorigenesis, whereas activation ofsevier Inc.Braf requires additional events to activate
PI3K-mTOR.Mutations ofCDKN2A, how-
ever, are highly common in all four kinds
of melanoma, suggesting this aspect of
the OIS barrier is important regardless of
melanoma driver event.
With regard tomelanocyte senescence,
it is worth noting that the results from
Damsky et al. (2015) are in agreement
with another study (Vredeveld et al.,
2012), which has also shown that PTEN
loss and PI3K activation in senescent
nevi can reverse the phenotype. What
these results suggest, therefore, is that
OIS in melanocytes is not an irreversible
state, in accord with prior studies ques-
tioning whether senescence is always
permanent. Using human fibroblasts,
Beause´jour et al. (2003) described two
types of senescence that appeared
phenotypically similar with regard to the
expression of senescence markers, but
which differed in their permanence. Spe-
cifically, p53-mediated ‘‘senescence’’
occurring in the absence of sustained
p16Ink4a expression could be readily
reversed through RB and p53 activation,
whereas senescence in the context of
high levels expression of p16Ink4a was
permanent (Beause´jour et al., 2003).
These in vivo studies would suggest that
melanocyte senescence is the imper-
manent kind, leading to the question of
whether such ephemeral growth arrest is
‘‘real senescence’’ or a less deep,
‘‘pseudo-senescence’’. An alternative ex-
planation is that a rare subpopulation of
Braf-expressing, nonsenescent mela-
nocytes within the growth-arrested nevi
exist, which only becomes evident in the
setting of accelerated proliferation result-
ing from mTOR activation.
In summary, this work from Damsky
et al. (2015) establishes that activation of
mTORC1 and mTORC2 is required to
bypass Braf-induced OIS and identifies
a miRNA family that regulates mTOR in
this setting. These data represent signifi-
cant progress in understanding how me-
lanocytes escape OIS at the very earliest
stages of transformation in Braf-induced
melanoma. This understanding may help
with the development of antimelanoma
therapeutics by further establishing the
critical role of persistent Raf-Mek and
PI3K-mTOR signaling in established tu-
mors. Additionally, the work has impli-
cations for the molecular pathogenesis
of precursor (e.g., nevus) to cancer (e.g.,
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Previewsmelanoma) progression with regard to
OIS, a topic with significance for many
cancer types beyond melanoma.REFERENCES
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In this issue ofCancer Cell, Schwartz and colleagues andCosta and colleagues demonstrate that inhibition of
PI3Ka or PI3Kb in cancer cells with hyperactivated PI3Ka or PI3Kb, respectively, activates the other isoform,
leading to a ‘‘rebound’’ of the PI3K activity through different compensation mechanisms.Phosphoinositide 3-kinases (PI3Ks) con-
tribute to many cellular processes, in-
cluding cell growth, survival, migration
and stress responses, cell cycle progres-
sion, and intracellular vesicular transport
(Vanhaesebroeck et al., 2012). At the
plasma membrane, PI3Ks catalyze the
production of 3-phosphoinositides that
coordinate the localization and activation
of lipid-binding proteins such as Akt ki-
nase. Activated Akt modulates the func-
tion of numerous substrates involved in
the regulation of cell survival and growth
as well as cell cycle progression.
There are three classes of PI3Ks that
differ in structure and function (Vanhaese-
broeck et al., 2010). Class I PI3Ks, which
are the best studied, are heterodimers
composed of a regulatory subunit (often
referred to as p85) and one of four
catalytic subunits (p110a, b, d, and g).
Although PI3K isoforms have highlysimilar structures and enzymatic activ-
ities, they have differing, nonredundant
functions.
Given the key role of PI3K in important
biological processes, it is not surprising
that the PI3K/Akt signaling cascade is
one of the most frequently altered path-
ways in human cancers. Oncogenic
activation of PI3K results from somatic
mutation/amplification of PIK3CA encod-
ing the p110a subunit, loss of the PI3K
negative regulator PTEN, mutation/ampli-
fication of various upstream signaling
components, or other nongenetic mecha-
nisms. The oncogenicity of p110a
has recently attracted much attention,
because large-scale genomic studies
have revealed that PIK3CA is the most
commonly mutated oncogene in many
cancer types (Lawrence et al., 2014).
Although non-a PI3K isoforms are less
frequently mutated, experimental datasupport their oncogenic potential (Kang
et al., 2006).
The identification and development of
PI3K inhibitors as anticancer therapies
has proceeded rapidly over the last few
years. Both isoform-specific and non-
specific (‘‘pan-PI3K inhibitors’’) inhibitors
have been generated. These agents,
which include compounds with varying
degrees and combinations of isoform
specificity, have been intensively exam-
ined in a large number of early phase clin-
ical trials (Rodon et al., 2013). In solid
tumors, themost advanced of these com-
pounds have entered or completed enrol-
ment of randomized phase III trials, the
results of which are eagerly awaited.
However, despite the early excitement
around the potential for this targeted ther-
apeutic strategy, clinical activity has been
less dramatic than anticipated, and the
therapeutic index of some of these PI3K27, January 12, 2015 ª2015 Elsevier Inc. 5
